LCB 09A
Alternative Names: LCB-09ALatest Information Update: 28 Feb 2026
At a glance
- Originator Cellectar Biosciences; LegoChem Biosciences
- Developer Cellectar Biosciences; LigaChem Biosciences
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for research development in Unspecified in South Korea (Parenteral)
- 28 Feb 2026 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 04 Jan 2022 LCB 09A is available for licensing as of 04 Jan 2022. https://www.legochembio.com/rnd/partners.php?lang=e